APR 13 2026
Travere Therapeutics — Filspari (sparsentan) $TVTX
for focal segmental glomerulosclerosis
FDA approved Filspari (sparsentan) to reduce proteinuria in adult and pediatric patients with focal segmental glomerulosclerosis.
About
Focal segmental glomerulosclerosis is a kidney disease that scars the organ’s internal filtering units, leading to harmful protein loss in the urine and often progressing to kidney failure. Filspari (sparsentan) is a single molecule designed to simultaneously block two biological pathways that cause blood vessels to constrict and promote scar tissue formation. By tackling these dual drivers of kidney damage, this treatment may potentially slow the disease's progression and help protect long-term kidney function.
Pivotal trial
To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Filspari
- Travere wins FSGS approval for FILSPARI, a milestone for holders including Armistice Capital - Cyprus Mail
- Travere Therapeutics Faces Scrutiny as Investors Weigh Filspari Commercial Prospects - Investor Earnings Call - dars.gov.et
- TVTX: FILSPARI cements its role in rare kidney disease, with robust growth and pipeline innovation - TradingView
- Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy - Business Wire
- FDA Advisory Committee Waiver for FILSPARI® (sparsentan) in FSGS: Implications for First-in-Class Therapy - Vera Health
Sponsor Watch — recent news on Travere Therapeutics
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
- Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress